Immunogenic Research Foundation. Research and eduction for oligodynamic mineral hydrosols, and in particular, nano- or pico-scalar oligodynamic silver hydrosol.
CAP-CMV´s active immunogenic ingredient is Dense Bodies, produced in human CAP cells. Dense Bodies carry the most complete set of antigens and generate efficient B-cell and T-cell responses.
CAP-CMV´s active immunogenic ingredient is Dense Bodies, produced in human CAP cells. Dense Bodies carry the most complete set of antigens and generate efficient B-cell and T-cell responses.
Videregen is a spin-out regenerative medicine company created to address the chronic shortage of organs for transplantation through non-immunogenic, regenerative bespoke organ replacements.
GlycoVaxyn´s goal is to improve human health through the development of novel bioconjugate vaccines using its proprietary glycoprotein technology. GlycoVaxyn´s technology paves the way for synthesizing bioconjugate material to levels previously unattainab
immatics is a private biopharmaceutical company based in Tuebingen, Germany. We are focused on the discovery and development of innovative active immunotherapies against cancer. Our proprietary technology allows us to identify tumor-associated peptides (T
Home Page for Artificial Cell Technologies, Inc., a bionanotechnology company developing synthetic vaccines using ultra-thin multilayer polypeptide nanofilms
Intralymphatic immunotherapy for allergic diseases was pioneered at UCLA and publicly disclosed in 1983 at the Federation of American Societies for Experimental Biology
Home Page for Artificial Cell Technologies, Inc., a bionanotechnology company developing synthetic vaccines using ultra-thin multilayer polypeptide nanofilms
immatics is a private biopharmaceutical company based in Tuebingen, Germany. We are focused on the discovery and development of innovative active immunotherapies against cancer. Our proprietary technology allows us to identify tumor-associated peptides (T
Home Page for Artificial Cell Technologies, Inc., a bionanotechnology company developing synthetic vaccines using ultra-thin multilayer polypeptide nanofilms
immatics is a private biopharmaceutical company based in Tuebingen, Germany. We are focused on the discovery and development of innovative active immunotherapies against cancer. Our proprietary technology allows us to identify tumor-associated peptides (T
Home Page for Artificial Cell Technologies, Inc., a bionanotechnology company developing synthetic vaccines using ultra-thin multilayer polypeptide nanofilms
immatics is a private biopharmaceutical company based in Tuebingen, Germany. We are focused on the discovery and development of innovative active immunotherapies against cancer. Our proprietary technology allows us to identify tumor-associated peptides (T
Home Page for Artificial Cell Technologies, Inc., a bionanotechnology company developing synthetic vaccines using ultra-thin multilayer polypeptide nanofilms
immatics is a private biopharmaceutical company based in Tuebingen, Germany. We are focused on the discovery and development of innovative active immunotherapies against cancer. Our proprietary technology allows us to identify tumor-associated peptides (T
Home Page for Artificial Cell Technologies, Inc., a bionanotechnology company developing synthetic vaccines using ultra-thin multilayer polypeptide nanofilms
immatics is a private biopharmaceutical company based in Tuebingen, Germany. We are focused on the discovery and development of innovative active immunotherapies against cancer. Our proprietary technology allows us to identify tumor-associated peptides (T